Comparing the current results to its competitors, Cogent Biosciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 13.93 %, recorded in the same quarter.
Cogent Biosciences Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 178.19 %
April 9, 2024
The realm of cancer therapeutics is ever-expanding with groundbreaking research constantly contributing to novel strategies and interventions, striving to enhance clinical outcomes. Prominent in this arena is the development of targeted therapies, including ErbB2 inhibitors, which have revolutionized treatment paradigms for specific cancer subtypes. This article enunciates the burgeoning discoveries and the potential implications emanating from the research conducted by Cogent Biosciences, about their novel, highly potent, and selective CNS-penetrant ErbB2 inhibitor.ErbB2, also known as human epidermal growth factor receptor 2 (HER2), is a member of the epidermal growth factor receptor (EGFR) family, signify...
February 14, 2024
Cogent Biosciences, a leading biotechnology company focusing on the development of precision therapies for genetically driven diseases, has recently announced the completion of an oversubscribed private placement, raising an impressive $225 million. This significant financial boost is expected to support the company through its ongoing registration-directed clinical trials, which include the SUMMIT, PEAK, and APEX studies. With pro-forma cash, cash equivalents, and marketable securities projected to fund Cogent into 2027, this considerable investment brings promising implications for the company s future success.BodyCogent Biosciences has made great strides in the world of gene-targeted therapies, and this r...
The business model of Blueprint Medicines Corporation revolves around the development and commercialization of precision therapies for patients with genomically defined cancers and rare diseases. They actively pursue a strategy of genomically targeted drug discovery and development, utilizing advanced technologies and clinical expertise to bring potentially life-changing treatments to market. The company focuses on creating value through strategic collaborations, licensing agreements, and the commercialization of their innovative therapies.
Allakos Inc's business model revolves around developing and commercializing innovative therapeutic antibodies to treat allergic and inflammatory diseases.
TG Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for patients with hematological malignancies and autoimmune diseases.
Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.
Aeon Biopharma Inc.'s business model focuses on the development and commercialization of biopharmaceutical products, emphasizing innovation and collaboration for the advancement of healthcare.
Sources:
Cogent Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cogent Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
